Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- William Schelman, MD
Hutchmed
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arizona Oncology Associated, Pc-Hope
Tucson, Arizona, United States
- City of Hope
Duarte, California, United States
- Rocky Mountain Cancer Centers Midtown
Denver, Colorado, United States
- Johns Hopkins University - Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
- Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
- Holden Comprehensive Cancer Center, University of Iowa
Iowa City, Iowa, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
- Prisma Health - Upstate (itor)
Greenville, South Carolina, United States
- Sarah Cannon
Nashville, Tennessee, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- Mary Crowley Cancer Research
Dallas, Texas, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
- Texas Oncology, P.A.
Fort Worth, Texas, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Texas Oncology, P.A.
Tyler, Texas, United States
- Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Mar 2021
- Primary completion
- 30 Apr 2024
- Completion
- 27 Aug 2024
- Last update posted
- 8 May 2025
- Registered enrollment
- 87
- Registry id
- NCT04579757
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.